BMY vs CURX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and CURX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and CURX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

Curanex Pharmaceuticals is a developmental-stage drug company that discovers and develops botanical drugs (medicines derived from plant material) to treat inflammatory diseases. Its lead candidate, Phyto-N, is an extract from a single plant with anti-inflammatory activity that the company says works through multiple biological targets and mechanisms. Curanex has reported validating Phyto-N in animal models across six inflammatory conditions, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with moderate-to-severe ulcerative colitis as the primary indication. The company has no approved products and therefore no product revenue; its path to making money depends entirely on advancing Phyto-N through clinical trials and ultimately to FDA approval, or on licensing or partnering the asset.

Full CURX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BMY drivers: New product portfolio ramp; Oncology and immunology depth.
• CURX drivers: A single asset aimed at a large market; Long human-use history as the differentiator.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For CURX, curanex is a pre-revenue, pre-clinical micro-cap with an unusually narrow base: a single drug candidate that has not yet entered human trials, an IND filing only targeted for late 2026, and years of clinical work and regulatory review ahead before any potential approval.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; CURX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and CURX guides.

BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.

CURX. For a company like Curanex, traditional valuation metrics such as price-to-earnings or revenue multiples do not apply, because there is no revenue and losses are small only because the company has barely begun to spend on trials. What matters is the cash runway versus the cost of clinical development, the credibility of the IND and trial timeline, and how much dilution future financings may cause. The collapse from a $4.00 IPO price to well under $1.00, alongside a roughly $14 million market value, signals that the market is pricing in significant execution and financing risk rather than near-term clinical value.

Headline figures (approximate, early 2026): BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%; CURX shows stage Pre-clinical, pre-revenue, product revenue $0 (no approved products), net loss (fy2024) approx $0.4 million, cash (mar 31, 2025, pre-ipo) approx $0.2 million.

BMY and CURX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and CURX exposure against your real portfolio. It is not an investment adviser.